| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/21/2010 | WO2008131114A3 Pharmaceutical formulations containing lipoic acid derivatives |
| 01/21/2010 | WO2008131059A3 Intranasally administering curcumin in a bolus of helium gas to treat alzheimer's disease |
| 01/21/2010 | WO2008130312A8 A new process for the manufacturing of the compound 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1h-indole-5-carbonitrile 701 |
| 01/21/2010 | WO2008128045A8 Solid forms of (e) -1- (4- ( (1r, 2s, 3r) -1, 2, 3, 4-tetrahydroxybutyl) -1h-imidazol-2-yl)ethanone oxime |
| 01/21/2010 | WO2008116064A3 Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases |
| 01/21/2010 | WO2008107797A3 Lercanidipine hydrochloride polymorphs and an improved process for preparation of 1,1,n-trimethyl-n-(3,3-diphenylpropyl)-2-aminoethyl acetoacetate |
| 01/21/2010 | WO2008083107A3 Combinations of antifolate agent and methoxyamine in the treatment of cancer |
| 01/21/2010 | WO2007041130A3 Deazapurines useful as inhibitors of janus kinases |
| 01/21/2010 | US20100017901 Compositions Comprising MG29 Nucleic Acids, Polypeptides, and Associated Methods of Use |
| 01/21/2010 | US20100017900 Prostate Epithelial Androgen Receptor Suppresses Prostate Growth and Tumor Invasion |
| 01/21/2010 | US20100017897 Prrg4-associated compositions and methods of use thereof in methods of tumor diagnosis |
| 01/21/2010 | US20100017896 Filaggrin |
| 01/21/2010 | US20100016956 Triazole compounds and methods of making and using the same |
| 01/21/2010 | US20100016955 Triazole compounds and methods of making and using the same |
| 01/21/2010 | US20100016833 Devices for the Treatment of Vascular Aneurysm |
| 01/21/2010 | US20100016677 Devices for and Methods of Analyzing a Physiological Condition of a Physiological Subject Based on A Workload Related Property |
| 01/21/2010 | US20100016606 Preparation of amorphous hydrous esomeprazole magnesium |
| 01/21/2010 | US20100016565 Identification and characterization of an anthocyanin mutant (ant1) in tomato |
| 01/21/2010 | US20100016557 HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha |
| 01/21/2010 | US20100016448 Flashmelt oral dosage formulation |
| 01/21/2010 | US20100016447 Spray oil and method of use thereof for controlling turfgrass pests |
| 01/21/2010 | US20100016446 Stable water-based topical pharmaceutical creams and methods of making and using same |
| 01/21/2010 | US20100016445 Transdermal diethylstilbestrol for treating prostate cancer |
| 01/21/2010 | US20100016444 Methods and Compositions for Treating Mammalian Nerve Tissue Injuries |
| 01/21/2010 | US20100016443 Method for preparing particles comprising metal oxide coating and particles with metal oxide coating |
| 01/21/2010 | US20100016442 Small molecule solubilization system |
| 01/21/2010 | US20100016440 Alpha-aminoamide derivatives useful as anti-inflammatory agents |
| 01/21/2010 | US20100016439 Ophthalmic device having therapeutic agent delivery capability and method of forming same |
| 01/21/2010 | US20100016438 Granulated crystal compilation composed of pure organic minerals used in all food applications resulting in energy supplementation, diet and weight regulation, and medicinal effects |
| 01/21/2010 | US20100016437 Alpha-aminoamide derivatives useful in the treatment of cognitive disorders |
| 01/21/2010 | US20100016436 Transdermal Administration of Active Agents, in Particular Diclofenac |
| 01/21/2010 | US20100016435 Hybrid molecules having mixed vitamin d receptor agonism and histone deacetylase inhibitory properties |
| 01/21/2010 | US20100016434 Inhibitors of Egln3 Activity for the Treatment of Neurodegenerative Disorders |
| 01/21/2010 | US20100016433 Nerve-regenerating agent |
| 01/21/2010 | US20100016432 Resolvins: biotemplates for novel therapeutic interventions |
| 01/21/2010 | US20100016431 Genes encoding a novel type of lysophophatidylcholine acyltransferases and their use to increase triacylglycerol production and/or modify fatty acid composition |
| 01/21/2010 | US20100016430 Modified coconut oils with broad antimicrobial spectrum |
| 01/21/2010 | US20100016428 Use of polyunsaturated fatty acids for the primary prevention of major cardiovascular events |
| 01/21/2010 | US20100016427 External preparation comprising prostaglandin derivative |
| 01/21/2010 | US20100016425 Methods of treating an overweight or obese subject |
| 01/21/2010 | US20100016424 Production and use of derivatized homoserine lactones |
| 01/21/2010 | US20100016423 Use of dronedarone for the treatment of patients with arrhythmia and having an increase of creatinine level due to dronedarone administration |
| 01/21/2010 | US20100016422 Solid forms of (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2h-pyran-3,4,5-triol and methods of their use |
| 01/21/2010 | US20100016421 Methods for determining sensitivity to aminoflavones |
| 01/21/2010 | US20100016420 Composition for the Treatment of Resistant Cancers Comprising Oridonin |
| 01/21/2010 | US20100016419 Antibacterial composition |
| 01/21/2010 | US20100016418 Cannabinoids for use in the treatment of neuropathic pain |
| 01/21/2010 | US20100016417 Elastin protective polyphenolics and methods of using the same |
| 01/21/2010 | US20100016416 Oligonucleotide Conjugates |
| 01/21/2010 | US20100016415 Proteins Expressed by Mycobacterium Tuberculosis and not by BCG and their use as Diagnostic Reagents and Vaccines |
| 01/21/2010 | US20100016413 Pathotropic targeted gene delivery system for cancer and other disorders |
| 01/21/2010 | US20100016412 Inhibition of ornithine aminotransferase for the treatment of proliferative disorders |
| 01/21/2010 | US20100016411 Method of modulation of expression of epidermal growth factor receptor(egfr) involving mirna |
| 01/21/2010 | US20100016410 Methods and Compositions Related to Eosinophil Regulation |
| 01/21/2010 | US20100016409 Rna Nanoparticles and Nanotubes |
| 01/21/2010 | US20100016408 Modulating the cdc14b-cdh1-plk1 axis and methods for sensitizing target cells to apoptosis |
| 01/21/2010 | US20100016407 Combined Telomerase Inhibitor and Gemcitabine for the Treatment of Cancer |
| 01/21/2010 | US20100016406 Antisense RNA for Treating Cancer and Inhibition of Metastasis and Vectors for Antisense Sequestration |
| 01/21/2010 | US20100016405 Compositions and Methods for Inhibiting Expression of the MYC Gene |
| 01/21/2010 | US20100016403 Use of d-serine derivatives for the treatment of anxiety disorders |
| 01/21/2010 | US20100016402 Unit dose formulations of ketorolac for intranasal administration |
| 01/21/2010 | US20100016401 3-aza-bicyclo[3.1.0]hexane derivatives |
| 01/21/2010 | US20100016400 Azabicyclic muscarinic receptor antagonists |
| 01/21/2010 | US20100016399 GLYT1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders |
| 01/21/2010 | US20100016397 Pyrrole and Pyrazole DAAO Inhibitors |
| 01/21/2010 | US20100016396 Pyrazole compound |
| 01/21/2010 | US20100016395 Ophthalmic compositions of parasympathetic stimulants and anti-inflammatories for use in the treatment of presbyopia |
| 01/21/2010 | US20100016393 Novel hydrogen sulfate salt |
| 01/21/2010 | US20100016391 Isoxazoline Compounds Having MIF Antagonist Activity |
| 01/21/2010 | US20100016389 Indole acetic acids exhibiting crth2 receptor antagonism and uses thereof |
| 01/21/2010 | US20100016388 Salts of a Selective Beta-2 Andrenoceptor Agonist |
| 01/21/2010 | US20100016387 Method of treatment |
| 01/21/2010 | US20100016386 Selective glycosidase inhibitors and uses thereof |
| 01/21/2010 | US20100016385 Process and formulation containing epothilones and analogs thereof |
| 01/21/2010 | US20100016382 Pharmaceutical composition |
| 01/21/2010 | US20100016381 Stable emulsion composition |
| 01/21/2010 | US20100016380 TNF-alpha production inhibitors |
| 01/21/2010 | US20100016379 Terephthalamate Compounds and Compositions, and Their Use as HIV Integrase Inhibitors |
| 01/21/2010 | US20100016378 Method of preventing dihydropyridine compound from degradation |
| 01/21/2010 | US20100016377 Use of a p38 Kinase Inhibitor for Treating Psychiatric Disorders |
| 01/21/2010 | US20100016376 Caspase inhibitors based on pyridone scaffold |
| 01/21/2010 | US20100016375 1,5-diphenyl-3-pyridinylamino-1,5-dihydropyrrolidin-2-one as cb1 receptor modulator |
| 01/21/2010 | US20100016374 Compounds Which Inhibit the Glycine Transporter and Uses Thereof |
| 01/21/2010 | US20100016373 such as 1-methyl-1H-imidazole-4-carboxylic acid 4-(3-hydroxy-4-isobutyryl-2-trifluoromethyl-phenoxymethyl)-benzylamide; preferential modulatators of glutamate receptors, used as antidepressants and anxiolytic agents |
| 01/21/2010 | US20100016372 Benzimidazole Derivatives |
| 01/21/2010 | US20100016371 Indole Compounds |
| 01/21/2010 | US20100016370 Process for the preparation of esomeprazole magnesium in a stable form |
| 01/21/2010 | US20100016369 Aminotetrahydroindazoloacetic acids |
| 01/21/2010 | US20100016368 Aminotetrahydroindazoloacetic acids |
| 01/21/2010 | US20100016367 Bis-pyrinidium compounds |
| 01/21/2010 | US20100016366 Novel Compounds Active as Muscarinic Receptor Antagonists |
| 01/21/2010 | US20100016365 Substituted 4-amino-piperidines |
| 01/21/2010 | US20100016364 Method of predictive determination of responsiveness to pharmacological intervention |
| 01/21/2010 | US20100016363 Fixed Combination Dosage Forms for the Treatment of Migraine |
| 01/21/2010 | US20100016362 Stabilized pharmaceutical composition containing donepezil, process of producing same and method for stabilization |
| 01/21/2010 | US20100016361 Aryl carboxylic acid cyclohexyl amide derivatives |
| 01/21/2010 | US20100016360 Alpha7 nicotinic acetylcholine receptor inhibitors |
| 01/21/2010 | US20100016359 Methods for controlling sr protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control sr protein activity |
| 01/21/2010 | US20100016358 Gamma-globin inducer |
| 01/21/2010 | US20100016357 Use of Beta-Aminoalcohols for the Treatment of Inflammatory Disorders and Pain |